44 related articles for article (PubMed ID: 26924081)
1. Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.
Montal R; Oliva M; Taberna M; De Avila L; Rovira A; Cos M; Mañós M; Navarro V; Nogués J; Lozano A; Rodríguez L; Vilajosana E; Vázquez S; Mesia R
Clin Transl Oncol; 2016 Nov; 18(11):1140-1146. PubMed ID: 26960559
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).
Echarri MJ; Lopez-Martin A; Hitt R
Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927178
[TBL] [Abstract][Full Text] [Related]
3. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy.
Lu HJ; Lin JK; Chen WS; Jiang JK; Yang SH; Lan YT; Lin CC; Chang SC; Teng HW
Asia Pac J Clin Oncol; 2016 Sep; 12(3):207-15. PubMed ID: 26935130
[TBL] [Abstract][Full Text] [Related]
4. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
Oliveira-Silva RJ; Carolina de Carvalho A; de Souza Viana L; Carvalho AL; Reis RM
Recent Pat Anticancer Drug Discov; 2016; 11(2):170-83. PubMed ID: 26955963
[TBL] [Abstract][Full Text] [Related]
6. Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.
Peddi P; Paryani B; Takalkar A; Bundrick P; Ponugupati J; Nair B; El-Osta H
Onco Targets Ther; 2016; 9():705-9. PubMed ID: 26929641
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis.
Kassouf E; Tabchi S; Tehfe M
BioDrugs; 2016 Apr; 30(2):95-104. PubMed ID: 26927802
[TBL] [Abstract][Full Text] [Related]
8. Long-term survivor of metastatic squamous-cell head and neck carcinoma with occult primary after cetuximab-based chemotherapy: A case report.
Große-Thie C; Maletzki C; Junghanss C; Schmidt K
World J Clin Cases; 2021 Aug; 9(24):7092-7098. PubMed ID: 34540964
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-Based Therapeutic Strategies for Recurrent Advanced Squamous Cell Carcinoma of the Head and Neck: A Case Report and Literature Review.
Nie H; Chen T; He K; Liang C; Guo W; Shi X
Front Immunol; 2021; 12():680327. PubMed ID: 34367140
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the
Starzyńska A; Sejda A; Adamska P; Marvaso G; Sakowicz-Burkiewicz M; Adamski Ł; Jereczek-Fossa BA
Arch Med Sci; 2021; 17(1):207-217. PubMed ID: 33488873
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies in Cancer Therapy.
Zahavi D; Weiner L
Antibodies (Basel); 2020 Jul; 9(3):. PubMed ID: 32698317
[TBL] [Abstract][Full Text] [Related]
12. Approach to the Patient with Recurrent/Metastatic Disease.
Guigay J; Sâada-Bouzid E; Peyrade F; Michel C
Curr Treat Options Oncol; 2019 Jun; 20(8):65. PubMed ID: 31240480
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Taberna M; Oliva M; Mesía R
Front Oncol; 2019; 9():383. PubMed ID: 31165040
[TBL] [Abstract][Full Text] [Related]
14. Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.
Linares J; Rullan A; Taberna M; Vazquez S; Mesia R
Oral Oncol; 2016 Apr; 55():e4. PubMed ID: 26924081
[No Abstract] [Full Text] [Related]
15. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
Bowles DW; Keysar SB; Eagles JR; Wang G; Glogowska MJ; McDermott JD; Le PN; Gao D; Ray CE; Rochon PJ; Roop DR; Tan AC; Serracino HS; Jimeno A
Oral Oncol; 2016 Feb; 53():74-9. PubMed ID: 26705064
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.
Sukari A; Nagasaka M; Diab M; Al Sibai K; Atassi B; Elayoubi JA; Kim S; Küçük Ö
Clin Otolaryngol; 2019 Jul; 44(4):639-643. PubMed ID: 30784192
[No Abstract] [Full Text] [Related]
18. Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma.
Quan K; Xu KM; Zhang Y; Clump DA; Flickinger JC; Lalonde R; Burton SA; Heron DE
Semin Radiat Oncol; 2016 Apr; 26(2):112-9. PubMed ID: 27000507
[TBL] [Abstract][Full Text] [Related]
19. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
